Investors were more than relieved Tuesday on the news that Icagen Inc.'s ICA-105665 met its primary endpoint in a Phase IIa study measuring the drug's ability to reduce the photic-induced epileptiform EEG response in patients with epilepsy. (BioWorld Today) Read More
